Exagen Inc. Reports Strong Q3 2025 Performance

Tip Ranks

2025.11.05 05:10

I'm PortAI, I can summarize articles.

Exagen Inc. reported strong Q3 2025 performance with total revenue of $17.2 million, a 38% increase from Q3 2024. Key highlights include a 16% growth in AVISE CTD test volume and an average selling price of $441 per test. The company ended the quarter with $35.7 million in cash, despite a net loss of $7.1 million. Exagen aims for positive adjusted EBITDA by the end of 2025, with projected full-year revenue between $65 million and $70 million, focusing on growth and enhanced testing solutions.

Exagen Inc. is a prominent provider of autoimmune diagnostics, specializing in innovative testing solutions for chronic autoimmune conditions such as lupus and rheumatoid arthritis. The company operates in the healthcare sector, focusing on improving clinical outcomes through its comprehensive testing portfolio.

Exagen Inc. reported a robust performance for the third quarter of 2025, with a significant increase in revenue and improved financial metrics. The company achieved a record total revenue of $17.2 million, marking a 38% rise compared to the same period in 2024.

Key highlights from the earnings report include a 16% growth in AVISE CTD test volume and an increase in the average selling price to $441 per test. The company also ended the quarter with a strong cash position of $35.7 million. Strategic advancements included the commercial launch of seronegative RA markers and presentations at a major rheumatology conference.

Despite reporting a net loss of $7.1 million for the quarter, Exagen’s adjusted EBITDA showed improvement, reflecting better operational efficiency. The company remains optimistic about achieving positive adjusted EBITDA by the end of 2025, with expected full-year revenue between $65 million and $70 million.

Looking ahead, Exagen’s management is focused on maintaining its growth trajectory and enhancing its testing solutions to meet the evolving needs of the healthcare market. The company aims to continue its strategic initiatives to drive long-term value for stakeholders.